相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Researchers in Argentina reported that four of five hantavirus patients survived after receiving tocilizumab, a rheumatoid arthritis drug, compared to five deaths among patients who received only standard care. - The study represents the first use of tocilizumab in a compassionate use trial for hantavirus pulmonary syndrome, targeting the IL-6 inflammatory pathway that contributes to lung failure. - Multiple research teams are developing antibody treatments and vaccines for hantavirus, but limited funding and the virus's rarity have hindered progress despite mortality rates reaching 35-40%. - Recent cruise ship outbreak that killed three passengers has renewed attention to hantavirus research, with scientists hoping for increased investment in treatment development.
- Orca Bio presented new clinical data at ASH 2025 showing Orca-T with reduced intensity conditioning achieved low rates of graft-versus-host disease and disease relapse in patients aged 60-75 with blood cancers. - A Phase 3 observational analysis demonstrated Orca-T delivered 94% overall survival compared to 81% with conventional PTCy-based therapy, with significantly lower non-relapse mortality rates. - Patient-reported outcomes from the Precision-T Phase 3 study showed Orca-T recipients experienced faster quality of life recovery, fewer ICU stays, and lower rehospitalization rates compared to conventional transplant. - The investigational therapy is currently under FDA Priority Review with a target action date of April 6, 2026, for treating multiple hematologic malignancies.
- Johnson & Johnson MedTech reported promising one-year results from the DISRUPT BTK II study, showing 94.8% of patients avoided major amputation and 84.5% remained free from revascularization. - The study validated the Shockwave Peripheral Intravascular Lithotripsy System's effectiveness in treating severely calcified below-the-knee lesions in 250 patients with peripheral artery disease. - Among the 80% of patients with chronic limb-threatening ischemia, only 8.1% experienced amputation within one year, with significant clinical improvements observed. - The trial demonstrated durable vessel patency in 67.1% of patients and clinical improvement by at least one Rutherford Class in 75.5% of participants.
- SeaStar Medical has reached the halfway point in its NEUTRALIZE-AKI pivotal trial, enrolling 100 of the planned 200 adult patients with acute kidney injury requiring continuous renal replacement therapy. - The trial is evaluating the company's Selective Cytopheretic Device (SCD) therapy, which has received FDA Breakthrough Device Designation for treating AKI, a condition affecting over 200,000 adults annually in the U.S. - An independent Data Safety Monitoring Review Board will conduct a prespecified interim analysis of the trial's primary endpoint, with findings expected in Q3 2025.
• Stanford Health Care has expanded its partnership with Atropos Health to embed real-world evidence directly into clinical workflows and encounter notes, enhancing point-of-care decision making without disrupting physician workflow. • The integration will work alongside Stanford's ambient AI provider, DAX from Microsoft, to generate evidence that helps clinicians finalize their notes while remaining within their existing EHR environment. • This advancement builds on Stanford's multi-year collaboration with Atropos Health, which began as the "Green Button" research project at Stanford Medicine in 2011 and has evolved to support over 2,000 affiliated physicians.
- Orca Bio's investigational cell therapy Orca-T demonstrated statistically significant improvement in survival without moderate-to-severe chronic GvHD compared to standard stem cell transplants. - The pivotal Phase 3 Precision-T trial evaluated Orca-T in patients with various blood cancers including AML, ALL, high-risk MDS, and MPAL. - Results from this landmark study will be presented at the 51st Annual EBMT Meeting in Florence, Italy, marking a potential breakthrough in blood cancer treatment.
